Roxadustat: Not just for anemia
Roxadustat is a recently approved hypoxia-inducible factor prolyl hydroxylase inhibitor that has demonstrated favorable safety and efficacy in the treatment of renal anemia. Recent studies found it also has potential for the treatment of other hypoxia-related diseases. Although clinical studies have...
Saved in:
Main Authors: | Xiaoyu Zhu (Author), Lili Jiang (Author), Xuejiao Wei (Author), Mengtuan Long (Author), Yujun Du (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Roxadustat for Patients with Posttransplant Anemia: A Narrative Review
by: Xiaoxiao Tang, et al.
Published: (2023) -
Roxadustat on Renal Anemia with Macroinflammation: A Retrospective Cohort Study
by: Yan Tu, et al.
Published: (2024) -
The Efficacy and Safety of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis
by: Lijun Wang, et al.
Published: (2022) -
Assessment of the safety of Roxadustat for cardiovascular events in chronic kidney disease-related anemia using meta-analysis and bioinformatics
by: Xiangmeng Li, et al.
Published: (2024) -
Risk of infection in roxadustat treatment for anemia in patients with chronic kidney disease: A systematic review with meta-analysis and trial sequential analysis
by: Shan Chong, et al.
Published: (2022)